Shopping Cart
Remove All
Your shopping cart is currently empty
MK-0429 is an orally active, selective, and nonpeptide antagonist of αvβ3 integrin (IC50: 80 nM).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $286 | 7-10 days | 7-10 days | |
| 5 mg | Inquiry | 7-10 days | 7-10 days | |
| 10 mg | Inquiry | 7-10 days | 7-10 days | |
| 1 mL x 10 mM (in DMSO) | Inquiry | 7-10 days | 7-10 days |
| Description | MK-0429 is an orally active, selective, and nonpeptide antagonist of αvβ3 integrin (IC50: 80 nM). |
| Targets&IC50 | αvβ3 integrin:80 nM, α5β1:12.2 nM (fibronectin-binding), αvβ5 integrin:0.1 nM (vitronectin-binding), αvβ8 integrin:0.5 nM (LAP-binding), αvβ6 integrin:0.7 nM (LAP-binding), αvβ1 integrin:1.6 nM (fibronectin-binding) |
| In vivo | MK-0429 is safe and efficacious in obviously reducing melanoma metastasis in the lungs. MK-0429 (100 or 300 mg/kg, p.o., twice daily b.i.d., 2 weeks) decreases metastatic tumor colony formation and area in the lungs [1]. |
| Synonyms | L-000845704 |
| Molecular Weight | 439.51 |
| Formula | C23H29N5O4 |
| Cas No. | 227963-15-7 |
| Relative Density. | 1.36 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (568.82 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.